Funding for this research was provided by:
National Institute of Mental Health (NCT01851356)
Received: 5 March 2018
Accepted: 30 May 2018
First Online: 3 July 2018
Ethics approval and consent to participate
: This study was approved by the Combined Neuroscience Institutional Review Board of the National Institutes of Health. All participants gave written informed consent before entry into the study.
: Drs. Salvadore, Drevets, and Kolb are full-time employees and shareholders of Janssen Pharmaceuticals, Inc. Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine and (2<i>S</i>,6<i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.